Table 1 Univariate and multivariate Cox regression analysis predicting OS in patients with lymphoma in training cohort
Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
HR (95%CI) | P-value | HR (95%CI) | P-value | |
Sex | ||||
Female | 1(ref.) | |||
Male | 1.17(0.986–1.39) | 0.072 | ||
Age | ||||
≤55 | 1(ref.) | 1(ref.) | ||
56–65 | 1.46(1.19–1.81) | < 0.001 | 1.400(1.133–1.732) | 0.002 |
≥66 | 3.03(2.49–3.69) | < 0.001 | 2.440(1.994–2.984) | < 0.001 |
Medical insurance | ||||
Residents | 1(ref.) | |||
Employees | 0.938(0.774–1.14) | 0.516 | ||
Others | 1.12(0.89–1.41) | 0.333 | ||
Pathologic type | ||||
Hodgkin | 1(ref.) | 1(ref.) | ||
Non- Hodgkin | 2.2(1.5–3.21) | < 0.001 | 2.138(1.435–3.187) | < 0.001 |
B symptoms | 1.53(1.04–2.25) | 0.031 | 1.444(0.969–2.152) | 0.071 |
Ann Arbor Stage | ||||
I-II | 1(ref.) | 1(ref.) | ||
III | 1.42(1.13–1.78) | 0.003 | 1.039(0.822–1.315) | 0.748 |
IV | 2.39(1.95–2.93) | < 0.001 | 1.551(1.252–1.923) | < 0.001 |
Chemotherapy | 0.585(0.476–0.718) | < 0.001 | 0.778(0.623–0.971) | 0.026 |
Targeted therapy | 0.656(0.54–0.797) | < 0.001 | 0.756(0.612–0.936) | 0.010 |
Immunotherapy | 0.17(0.024–1.21) | 0.077 | ||
LDH > 245U/L | 2.47(2.09–2.91) | < 0.001 | 1.639(1.365–1.967) | < 0.001 |
β2-microglobulin > 2.5 mg/L | 2.72(2.28–3.24) | < 0.001 | 1.577(1.298–1.917) | < 0.001 |
CRP > 10 mg/L | 3.47(2.9–4.14) | < 0.001 | 2.196(1.807–2.669) | < 0.001 |